On Monday we wrote that GSK’s habit of cutting losing programs fast—camlipixant in chronic cough, the Alector neurodegeneration pact before it—was defensible discipline that came with a cost. Fewer shots on goal means more weight on each remaining one, and we said the Nuvalent lung cancer drugs now had to carry the load. Three days later, they started to.
The FDA approved Jideytro (zidesamtinib) for patients with ROS1 positive non small cell lung cancer who have already received a ROS1 inhibitor. It is the first approval to come out of GSK’s $10.6 billion Nuvalent acquisition, the company’s largest deal in a decade. And remarkably, it is GSK’s first approved lung cancer product ever. For a company that has been criticized for a thin oncology position relative to its peers, entering lung cancer through the front door with a targeted therapy in the same month it closed the deal is a real strategic milestone.
Neladalkib, the ALK inhibitor from the same acquisition, remains under FDA review. If it lands too, the Nuvalent thesis is validated faster than anyone expected, and CEO Luke Miels gets to point at a deal that paid off inside a year.
The week also delivered a big myeloma readout from J&J, a transatlantic regulatory split on AstraZeneca’s breast cancer drug, the generic tariff countdown going official, and the clearest sign yet that the sector’s labor bleeding has slowed.
GSK’s First Lung Cancer Drug, From a Deal That Closed Last Month
What Happened: The FDA approved GSK’s Jideytro (zidesamtinib) for adults with locally advanced or metastatic ROS1 positive NSCLC who have received a prior ROS1 kinase inhibitor.
What ROS1 Lung Cancer Is and Why This Approval Matters
ROS1 rearrangements are genetic alterations that drive a small but meaningful share of non small cell lung cancers. Patients with ROS1 positive tumors typically respond well to first generation ROS1 inhibitors like crizotinib and entrectinib, but most eventually develop resistance and progress. The previously treated setting—patients who have already failed a ROS1 inhibitor—has had limited options, making it a logical and important entry point for a new drug.
Jideytro is designed to overcome the resistance mutations that develop during treatment with existing ROS1 inhibitors. By targeting the resistant forms of the rearranged protein, it addresses the exact clinical problem that patients face when their first ROS1 drug stops working. That specificity is what makes targeted oncology work: find the molecular driver, match a drug to it, and when resistance develops, bring a drug that hits the resistant form.
Why This Is More Than One Niche Approval
The ROS1 positive population is not enormous on its own. But this approval does several things for GSK beyond the immediate patient population.
It establishes GSK with lung cancer prescribers for the first time. The company has never had an approved product in lung cancer, which means it has never had the physician relationships, the payer coverage infrastructure, or the commercial presence in the lung cancer treatment landscape. Jideytro creates that foundation.
It validates the Nuvalent acquisition thesis faster than expected. GSK paid $10.6 billion for two late stage drugs and got its first approval within weeks of closing the deal. That speed is unusual for large acquisitions, where post close integration and regulatory timelines typically mean years before the acquired assets produce revenue.
And it reframes the fast cutting strategy we questioned Monday. Killing camlipixant and walking from Alector left GSK with fewer pipeline shots. The Jideytro approval demonstrates the offsetting logic: cut programs whose data disappoint, and concentrate resources on assets that are already de risked enough to reach the market quickly. If neladalkib (ALK lung cancer, still under review) also lands, GSK will have validated a capital allocation approach that many had questioned.
BioSpace noted that between Nuvalent and a 2023 Hansoh deal, GSK now has several other lung cancer assets in late stage development. The company went from zero lung cancer products to a growing franchise in a single quarter. That is what a well timed $10.6 billion check can do.
J&J’s Bispecific Combination Delivered a Big Number in Earlier Myeloma
What Happened: J&J reported topline results from the MonumenTAL 6 study showing its bispecific antibodies Tecvayli and Talvey produced an 89% improvement in progression free survival and a 62% overall survival benefit in earlier lines of multiple myeloma treatment.
Why Moving Bispecifics Earlier Matters
Tecvayli (teclistamab, targeting BCMA and CD3) and Talvey (talquetamab, targeting GPRC5D and CD3) are both approved in heavily pretreated myeloma—patients who have exhausted multiple prior therapies. The MonumenTAL 6 data move the combination into earlier treatment lines, where the patient populations are larger, the disease is more treatable, and the potential for durable responses is greater.
Numbers of this magnitude—89% PFS improvement and 62% OS benefit—are striking. If they hold in the full dataset, they would strengthen the case for using bispecific antibodies before patients exhaust other options, rather than reserving them as salvage therapy. The logic is intuitive: a powerful treatment works better when the disease is less advanced and the patient is less debilitated by prior therapy.
For J&J, the MonumenTAL 6 result is a welcome counterpoint to the oncology sales miss that opened Q2 earnings. The miss raised questions about whether J&J’s oncology franchise was losing competitive ground. The myeloma data answer that question with numbers that would be practice changing if confirmed. J&J now has two bispecific antibodies targeting different antigens (BCMA and GPRC5D) in a combination that could define how earlier line myeloma is treated.
The competitive dynamics in myeloma continue to intensify. Lilly’s Kelonia in vivo CAR T program targets BCMA through a completely different modality. Gilead’s anito cel (from the Arcellx acquisition) also targets BCMA. The convergence of bispecific antibodies and CAR T therapies on the same disease through different mechanisms and delivery approaches gives myeloma patients more options than they have ever had. MonumenTAL 6 says J&J’s bispecific approach belongs at the top of that conversation.
Europe Said Yes to a Drug America’s Advisers Said No To
What Happened: AstraZeneca’s camizestrant won a positive opinion from Europe’s CHMP less than a month after a U.S. advisory panel voted against it. The drug is a next generation selective estrogen receptor degrader for breast cancer.
What Happens When the Same Data Get Opposite Reads
Divergent regulatory outcomes on identical clinical evidence are uncommon and always instructive. When the U.S. advisory committee voted against camizestrant, the market treated it as a significant setback for AstraZeneca’s breast cancer franchise. When the European CHMP issued a positive opinion weeks later, using the same data package, it created one of the sharpest transatlantic regulatory splits of the year.
The divergence typically reflects different weightings of the same tradeoffs. How much benefit is enough? How much toxicity is acceptable? What are the available alternatives in each market, and do they change the bar? European reviewers may have placed more weight on the unmet need in the specific patient population camizestrant targets, or they may have applied a different threshold for the magnitude of improvement relative to existing options. Both assessments can be reasonable. They simply reflect different institutional judgments on the same evidence.
For AstraZeneca, the European path forward softens a blow that looked worse a month ago. The FDA has not yet issued its own decision and is not bound by the advisory committee vote—the agency has overruled its advisers before. So camizestrant still has a U.S. path, even if it is now harder. A European approval provides commercial revenue, physician experience, and real world data that can support a U.S. resubmission or a follow up conversation with the FDA.
For the broader industry, the split is a reminder of two things. First, a negative advisory committee vote is a setback, not a verdict. The FDA makes its own call. Second, a drug’s commercial life can look very different on either side of the Atlantic, and companies increasingly build launch strategies that account for different timelines, labels, and market dynamics by region.
The Generic Tariff Countdown Is Now Official
What Happened: President Trump set a countdown for tariffs on imported generic medicines, ending an exemption that had shielded the copycat drugs behind the bulk of U.S. prescriptions. He framed the levies as a penalty for companies that decline to shift production onto American soil.
The Punitive Framing Changes the Calculation
Yesterday we covered the economic reality: generic drugs compete on pennies, production concentrated overseas because domestic manufacturing costs more, and tariffs raise import costs without making domestic production profitable by themselves. That analysis stands. But the framing Trump used—explicitly calling the tariffs a penalty for not reshoring—changes how the industry has to respond.
A tariff framed as revenue policy can be negotiated, adjusted, and worked around through trade agreements and exemptions. A tariff framed as punishment for a specific behavior—not bringing manufacturing home—creates a different kind of pressure. It tells the industry that the administration views offshore generic production as a choice it wants to penalize rather than an economic reality it wants to manage. That framing makes it harder for pharma lobbyists to argue for exemptions, because the counter argument from the administration is straightforward: move the plants and the tariff goes away.
Indian pharmaceutical stocks fell sharply on the news, which tells you where the market thinks the exposure sits. India supplies a large share of America’s generic medicines, and its generic manufacturers are the ones most directly threatened by import tariffs that make their products less competitive. India’s Lupin moved two of its cancer development programs into a newly formed U.S. based biotech, an early example of how Indian companies may respond—not by moving their entire manufacturing base, but by restructuring specific programs to reduce their U.S. tariff exposure.
The Section 232 pharmaceutical tariffs take effect for large companies one week from today, July 31. The generic tariffs announced this week are separate and start in 2028. Together they represent a policy environment where both branded and generic drug imports face rising costs, creating pressure across the entire supply chain to shift manufacturing toward the United States.
The Clearest Sign the Sector Turned: Companies Stopped Cutting People
What Happened: Biopharma layoffs would have to double in the second half for 2026 to match 2025’s total, according to BioSpace. Fewer companies are making or planning workforce reductions year over year.
Why This Signal Matters More Than Revenue
Revenue in a given quarter reflects product cycles, pricing dynamics, and decisions made years ago. Deal announcements reflect the ambitions of a handful of large buyers. But layoffs reflect something different: what management teams across hundreds of companies believe about their own futures right now.
Cutting people is expensive. It is damaging to morale. It costs money to pay severance, and it costs even more to rehire and retrain when conditions improve. Companies do it when they are convinced they have to. When layoffs slow broadly—not at one company or in one quarter, but across the sector over months—it means confidence has genuinely returned.
After the brutal stretch of 2024 and 2025, when the industry shed workers relentlessly (Takeda 4,500, Gilead 87% of Arcellx, Genentech restructuring deep enough to reach a 30 year veteran, enGene halved, Neumora cut 35%, Fulcrum cut 85%), the slowdown we first flagged in early July is holding. The aggregate pace of cuts has declined enough that the second half would need to be dramatically worse than the first to match last year’s total. That is not impossible—individual restructurings continue, and M&A itself eliminates roles—but the direction of travel is toward fewer cuts, not more.
It is not uniform. Clinuvel is cutting up to a fifth of its staff as it relocates its headquarters to the United States. Novartis shed 322 workers. Individual companies continue to right size around strategic priorities. But the sector wide wave that defined the past two years has broken. Combined with the reopened IPO window, the record M&A, and the friendlier regulatory posture, the case for a real recovery is now supported by multiple independent indicators rather than sentiment alone.
Strategic Themes
1. GSK’s Nuvalent Deal Paying Off Inside a Year Changes How the Market Views the Company
From thin oncology pipeline to first lung cancer approval in weeks. That is a narrative shift. If neladalkib (ALK lung cancer) also lands, GSK will have validated a strategy of buying late stage de risked assets, cutting programs that disappoint, and concentrating resources on the winners. The Nuvalent thesis—pay $10.6 billion for two drugs already under review, get approvals fast, enter a therapeutic area you have never been in—is the most aggressive version of the “buy rather than build” approach that the entire industry has adopted. Three days was all it took from our Monday question about whether GSK’s remaining pipeline could carry the load to the first answer: yes, at least on this one.
2. J&J’s Myeloma Numbers Rebalance a Soft Earnings Open
89% PFS improvement. 62% OS benefit. In earlier treatment lines. If MonumenTAL 6 holds, J&J’s bispecific combination becomes one of the most important datasets in myeloma this year. The timing helps too—arriving in the same earnings season where J&J’s oncology sales disappointed, the myeloma result provides evidence that the franchise’s best data may be ahead of it rather than behind it.
3. The Camizestrant Split Shows That Regulatory Outcomes Are Not Binary
A negative U.S. advisory vote and a positive European opinion on the same data. The same drug can be rejected in one market and approved in another based on how the regulators weigh the same tradeoffs. For companies managing global portfolios, this is a reminder to plan for geographic divergence rather than assume a single global outcome. For investors, a negative advisory committee vote may overcorrect a stock precisely because the market treats it as final when it is not.
4. The Layoff Slowdown Is the Most Honest Health Signal of Q2
Companies do not stop cutting until they believe the outlook justifies keeping people. The sector stopped cutting broadly enough that the second half would need to double its pace to match 2025. That is a stronger indicator of genuine recovery than any single quarter’s revenue line or any conference’s mood. The recovery is real. It is not uniform. And the early stage funding drought underneath it remains the quiet risk that nobody headlines but that determines the health of the pipeline five to ten years from now.
Frequently Asked Questions
What is Jideytro?
GSK’s zidesamtinib, approved for ROS1 positive NSCLC in patients who have received a prior ROS1 inhibitor. The first approval from the $10.6B Nuvalent acquisition and GSK’s first ever lung cancer product. Neladalkib (ALK lung cancer) from the same deal remains under review.
What were the J&J myeloma numbers?
Tecvayli plus Talvey showed 89% improvement in progression free survival and 62% overall survival benefit in earlier lines of myeloma treatment (MonumenTAL 6 study). Numbers that would be practice changing if confirmed in the full dataset.
What is the camizestrant regulatory split?
AstraZeneca’s breast cancer drug received a positive European CHMP opinion weeks after a U.S. advisory panel voted against it. Same data, opposite reads. The FDA has not yet issued its own decision and is not bound by the advisory vote.
Are the generic tariffs the same as Section 232?
No. Section 232 tariffs on branded pharmaceutical imports take effect July 31 for large companies. The generic drug tariffs announced this week are a separate policy starting in 2028, explicitly framed as a penalty for not reshoring generic production. Together they create rising costs on both branded and generic drug imports.
How are layoffs trending?
Layoffs would need to double in the second half to match 2025’s total. Fewer companies are cutting. Individual restructurings continue (Clinuvel, Novartis), but the sector wide wave has broken. The slowdown is the clearest indicator of genuine recovery across the industry.
What is coming next week?
Q2 earnings continue. BMS KarXT Alzheimer’s psychosis readout expected late July. Section 232 tariffs effective July 31. Replimune RP1 FDA response expected in August.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
GSK’s Nuvalent Deal Is Paying Off. We analyze what neladalkib decides for the full acquisition thesis, assess whether the fast cutting plus late stage buying strategy is now vindicated, and evaluate how quickly GSK can build a meaningful lung cancer franchise from a standing start.
When Regulators Split on the Same Data. We explain what the camizestrant divergence tells you about modeling regulatory risk, identify which other pending decisions could produce similar geographic splits, and assess AstraZeneca’s path forward on both sides of the Atlantic.
Layoffs Slowing Is the Real Health Signal. We detail what the slowdown means for the second half workforce outlook, where the unevenness still bites (early stage, individual restructurings, M&A driven cuts), and why this indicator matters more than any single earnings print.
Plus: J&J MonumenTAL 6 myeloma franchise implications, generic tariff countdown analysis, Lupin U.S. restructuring as Indian response template, Section 232 countdown (7 days), and the full H2 catalyst calendar.
About BioMed Nexus
BioMed Nexus delivers institutional grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep dive analyses cut through the noise to deliver the strategic insights that drive better decision making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
